Skip to main content
. 2018 Jan 24;217(11):1761–1769. doi: 10.1093/infdis/jiy039

Table 3.

Properties of the Selected Lead Compounds

Cmpd. Plasma Liver Liver/Plasma Ratioc CMax/EC50d
TMax (h) CMax (μM) T1/2
(h)
AUC24h (h·μM) bAUC (h·μM) TMax (h) CMax (μM) T1/2
(h)
AUC24h (h·μM) bAUC (h·μM)
1 a 0.25 3.2 2.0 9.8 9.8 0.083 87 2.0 262.3 262.5 26.8 3.6
2 0.083 5.3 6.7 27.6 29.9 0.083 54.7 8.5 431.1 497.0 15.6 3.2
3 0.083 3.5 4.7 7.3 7.5 0.083 80.43 4.8 145.1 149.0 19.9 35.0
7 0.25 6.9 2.6 27.2 27.2 0.25 52.6 4.6 289.1 296.5 10.6 5.3
9 0.083 1.8 12.0 2.9 3.6 24 161.12 ND 3536.8 ND 1231.0 5.4
12 0.083 6.9 15.3 8.0 9.8 4 95.98 ND 1908.4 ND 239.9 3.4

a 50 mg/kg dosage. AUC24, AUC’ and CMax have been reduced to one-fifth of their measured value for comparison.

b Extrapolated total exposure from a single dose.

c Ratio of AUC24.

d 50% viral inhibition (EC50), see Table 1.

Abbreviations: AUC, area under the curve extrapolated from time 0 to infinity (total compound exposure); AUC24h, area under the curve (compound exposure) from time 0 to 24h; CMax, maximum concentration; Cmpd, compound; ND, not determined; TMax time to reach Cmax; T1/2, half-life.